SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Haseltine who wrote (273)4/9/1998 4:10:00 PM
From: Richard Haugland  Read Replies (1) | Respond to of 783
 
Biochem Pharma Issues Statement Following Information Received From The Muc Police

biz.yahoo.com



To: Haseltine who wrote (273)4/12/1998 8:19:00 PM
From: Wilfredo Pagani  Read Replies (1) | Respond to of 783
 
The resistance in HIV and Hep C virus is far more common than with hep B virus. Apparently the first two are younger virus with a not so stable genetic code that may be associated with mutations and strange terms as quasispecies for hepatitis C. That is why is so difficult to develope a vaccine for this two viruses. Hep B already had a vaccine and the rate of mutations developing resistance should be less and not of great importance. WPagani


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News